Expertise in
20
conditions

Jianfeng N. Zhou

1095 Jiefang Avenue, 
Wuhan, CN 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
20
conditions
1095 Jiefang Avenue, 
Wuhan, CN 

Overview

Jianfeng Zhou practices practicing medicine in Wuhan, China.

Zhou is highly rated in 20 conditions, according to our data. Their clinical expertise encompasses Leukemia, B-Cell Lymphoma, Non-Hodgkin Lymphoma, Hemophagocytic Lymphohistiocytosis, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 382 peer reviewed articles and participating in 9 clinical trials.

Locations

1095 Jiefang Avenue, Wuhan, China
Other Locations
No.1 Youyi Road, Youyi, 400016, China
Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China
No.72 Guangzhou Road, Nanjing, 210000, China
NO.1095 Jie Fang Avenue, Wuhan, 430030, China
1095# Jiefang Ave, Wuhan, 430030, China
No. 28 Fuxing Road, Beijing, 100853, China
NO. 1095, Jiefang Road, Wuhan, 430030, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Exploratory Study of Fully Human Anti-GPRC5D Chimeric Antigen Receptor T Cells (CAR-GPRC5D) in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
An Exploratory Study of Fully Human Anti-GPRC5D Chimeric Antigen Receptor T Cells (CAR-GPRC5D) in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Enrollment Status: Recruiting
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drug: CAR-T (CAR-GPRC5D)
Study Phase: Phase 1
A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Enrollment Status: Recruiting
Publish Date: July 31, 2024
Intervention Type: Biological
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
A Multicenter, Randomized, Open-label, 2-arm, Phase II Study With a Safety lead-in Phase Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Enrollment Status: Completed
Publish Date: April 30, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2025
Intervention Type: Combination product
Study Drugs: Selinexor+Bortezomib+Dexamethasone, Bortezomib+Dexamethasone
Study Phase: Phase 3
A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or No Standard of Care Existed
A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or No Standard of Care Existed
Enrollment Status: Completed
Publish Date: August 23, 2023
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 1
Phase I Clinical Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in the Treatment of Patients With Relapsed/Refractory Extramedullary Multiple Myeloma
Phase I Clinical Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in the Treatment of Patients With Relapsed/Refractory Extramedullary Multiple Myeloma
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug
Study Drugs: Selinexor, CT103A
Study Phase: Phase 1
A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
A Phase I Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Enrollment Status: Completed
Publish Date: March 18, 2022
Intervention Type: Biological
Study Drug: pCAR-19B cells
Study Phase: Phase 1
View 6 Less Clinical Trials

382 Total Publications

Dynamic lysine acetylation and succinylation of platelet proteins regulates platelet storage lesion: mechanistic insights from multi-omics.
Dynamic lysine acetylation and succinylation of platelet proteins regulates platelet storage lesion: mechanistic insights from multi-omics.
Journal: Annals of medicine
Published: February 23, 2026

Frequently Asked Questions about Jianfeng N. Zhou

Is Jianfeng N. Zhou a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Jianfeng N. Zhou is classified as an Distinguished expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jianfeng N. Zhou participate in research or clinical trials?

Yes. Jianfeng N. Zhou has published 382 articles and abstracts on conditions like Leukemia. You can view a list of Jianfeng N. Zhou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhou's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 50 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile